Skip to main content
Egyptian Liver Journal
Download PDF

The novel approach for non-invasive diagnostic biomarkers from an early stage of NAFLD to advanced fibrosis

Egyptian Liver Journal volume 13, Article number: 51 (2023) Cite this article

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disorders that will be started from more than or equal to 5% of fats deposited into the liver hepatocyte cells and progressively leads to steatosis, further increment in fat deposition, and signature of inflammatory markers which cause the non-alcoholic steatohepatitis (NASH) condition. Due to a lack of diagnosis and effective treatment, NASH is converted into liver cirrhosis or hepatocarcinoma, which indicates the irreversible stage of the disease and finally recommends liver transplantation for patient survival. However, nowadays, several clinical biomarkers are identified, and most of the new biomarkers are in the developmental stage, but still the diagnosis of each stage of fatty liver is unaccomplished. So, in this review article, we try to present all current mechanistic perspectives to find the non-invasive biomarkers which could be the best approach in the future to diagnose fatty liver disease in each stage.

Main text

NAFLD is a growing phase disease if properly not taken care of by the patient. There are certain factors that can make fast progress in the disease stage like NAFLD to advance liver fibrosis or hepatocarcinoma. We describe to the best extent how different types of disease stages in the case of the fatty liver could be diagnosed using non-invasive biomarkers. A certain type of mechanistic pathophysiology approach is used to differentiate each stage of fatty liver disease like serum biomarkers (inflammatory cytokines), lipoproteins, micro-RNAs, gut microbiome-associated biomarkers, lipid droplet-associated perilipins, apolipoprotein E, the role of dihydroceramide, and gene expression studies.

Conclusions

Recent advancements in diagnostic biomarkers research focused on non-invasive methods, but the diagnosis of different stages of fatty liver disease is still inconclusive. We tried to cover all the potential non-invasive biomarkers in our manuscript. This review helps the researchers to develop possible diagnostic biomarkers for each stage of liver disease.

Introduction

Epidemiology of NAFLD/NSAH

Non-alcoholic fatty liver disease was first recognized in 1980 as a multifaceted metabolic disorder. It is one of the most widespread illnesses affecting modern humans. According to estimates, 25.24% of the world’s population now has NAFLD, with the Middle East and South America having the highest incidence rates. Over the past 20 years, NAFLD has emerged as the most prevalent chronic liver disease worldwide. In Japan, a study of 3271 individuals was conducted which suggests that NAFLD is more common in obese patients, that is, 68.5% developed NAFLD as compared to only 15.2% of nonobese patients [1]. The prevalence of NAFLD is higher in participants with T2DM and those who are obese (51.83% in diabetic participants vs. 30.76% in nondiabetic participants).

Recent studies claim that among 1812 biopsy samples of NAFLD patients between 2006 and 2019 were combined into a selected clinical dataset across nine Asian nations; 21.6% of patients with biopsy-confirmed NAFLD were not fat. Additional variables found using random forest analysis that is helpful for detecting nonobese NAFLD patients with advanced liver disease include hemoglobin, GGT, waist circumference, and cholesterol [2].

In a study conducted among US adults by the National Health and Nutrition Examination Survey from 2017 to 2018, NAFLD was independently linked to men, older age, and Hispanic race. Non-Hispanic whites between the ages of 50 and 79 had the greatest prevalence rates of NAFLD. However, compared to non-Hispanic whites, NAFLD prevalence rates were higher in Hispanics at a younger age.

Out of the 4024 individual US adults, 56.7% aged ≥ 20 years had NAFLD by CAP. With the increase in obesity among youth, it is expected to increase in the NAFLD. However, it also suggests that the prevalence of NAFLD was higher in men than in women [3].

Another clinical research analysis states the causes of chronic liver disease (CLD) in people, mainly adolescents and young adults between the ages of 15 and 29, over the past 10 years. Out of the many factors such as viral hepatitis, they found that NAFLD is the primary factor driving an increase in CLD incidence. Given the high rates of obesity and T2DM in the general population, which have made NAFLD one of the most widespread causes of liver disease in both adults and children, NAFLD can cause a considerable burden of CLD, particularly in people ages 20 to 29 [4].

In a systematic review and meta-analysis study conducted in 2019 for global NAFLD prevalence, it has been found that in a literature search of 17,244 papers, 245 of them were eligible studies involving 5,399,254 people. The combined global prevalence of NAFLD was 29.8%. The highest NAFLD prevalence was found in South America (3 studies, 5716 people), followed by North America (4 studies, 18,236 people). NAFLD grew from 21.9 to 37.3% between 1991 and 2019 according to trend analysis, with South America experiencing the largest annual change (2.7%), followed by Europe (1.1%). Despite regional heterogeneity, this suggests that NAFLD prevalence is generally rising globally [5].

Another group that studied the prevalence of NAFLD worldwide found that the estimated global prevalence of NAFLD is 32.4%. The prevalence considerably increased over time, rising from 25.5% in or before 2005 to 37.8% in or after 2016. Men were substantially more likely to have NAFLD as compared to women. According to estimates, there are 46.9 instances of NAFLD per 1000 people, 70.8 cases per 1000 people for men, and 29.6 cases per 1000 people for women. Men have much greater rates of NAFLD than women do, both in terms of incidence and prevalence [6].

According to a recent meta-analysis of NAFLD in China the following study was performed 66.21% in obese vs. 11.72% in lean. In China, the prevalence of NAFLD and the rising obesity rate are correlated (the prevalence from approximately 2% in 2000 to 7% in 2014). Additionally, T2DM and obesity raise the danger of simple steatosis developing into NASH, cirrhosis, and HCC. Notably, China has Asia’s highest prevalence, incidence, and yearly mortality rate from NAFLD. According to another meta-analysis of 93 research from 24 countries or regions, lean NAFLD affects 5.1% of the general population, while nonobese NAFLD affects 12.1% of persons. It is important to remember that NAFLD can occur in slim adults with normal waist circumference (12.9%) [7]. Another study in the US population suggested that high-quality diet (HQD), more physical activity, and college education were linked to lower NAFLD risk. Those with HQD who were physically active showed the lowest probability of developing NAFLD [8].

When compared to the demographics of the USA, where African-Americans (AA) make up 12% of the population, it was seen that they were underestimated in the study of 1026 people with NAFLD, making up just about 3% of the sample population. In reality, NAFLD may be present in 10 to 20% of nonobese Americans.

In Asian people, where the majority of “lean” NAFLD investigations have been done, “lean” NAFLD is most frequently observed. NAFLD may affect between 7 and 18% of Asia’s nonobese population (including China, Korea, and Japan) [1].

The burden of NAFLD is anticipated to expand further in the years to come, driven by continued rises in the incidence of obesity and T2DM as well as an aging population [9]. With increase in NAFLD, it is also becoming the root cause of hepatocellular carcinoma and cirrhosis [10] (Fig. 1).

Fig. 1
figure 1

Showing the conclusive current trend followed by the patient of nonalcoholic fatty liver disease based on their epidemiological data globally. The nonobese patient shows a very lower prevalence rate to develop the NAFLD when we compare with patients with already type 2 diabetes mellitus and obesity patient

Full size image

Non-alcoholic fatty liver disease

When fat continuously accumulates in over 5% of hepatocytes, then it is known to be non-alcoholic fatty liver disease (NAFLD) [11]. The emergence of NAFLD occurs due to disposition of fats. As per data gathered from epidemiological studies globally, related to obesity and type 2 diabetes cases, it leads to proportionality increment in NAFLD or NASH patients [12]. Modern lifestyle and diet patterns are responsible for the epidemic growth. It is proposed that in the recent times, more than 25% of the world population is suffering from NAFLD initial stage, whereas previously only 25% were suffering [5, 13,14,15]. The lack of specific non-invasive biomarkers to detect the exact stage of fatty liver disease is a major concern as this leads to the increasing severity of NAFLD and fibrosis. This increasing severity leaves no option other than liver transplantation to save the patient [16].

There are numerous diagnostic procedures and biomarkers on the market that can be used to identify the different stages of fatty liver disease. However, as of now, neither a distinct illness profile at later stages nor an early-stage diagnosis has been accurately identified. Understanding each step of the NAFLD is crucial [17].

NAFLD stages

Beginning of the fatty liver disease is marked with the continuous disposition of fat into the hepatocytes cell, and if there is coverage of more than 5% area in the cells, then there is emergence of early stage of non-alcoholic fatty liver disease (NAFLD) [18]. In the absence of remedies, the fat disposition progresses to the next stage of the disease where high amount of fats are accumulated. The accumulation of fats leads to formation of balloons, and this stage is referred to as liver steatosis [19].

When there is continuous growth pattern observed in steatosis, then the liver cells start entering into the red zone, and inflammatory damage occurs to the hepatocytes. This damage alters the normal physiology of the cells that leads to the marred state of the normal hepatic cellular system known as non-alcoholic steatohepatitis condition. In this stage, various types of inflammatory cytokines are activated and also activate the hepatic stellate cells which is further leading to increased expression of IL-6, IL-beta, C-reactive protein (CRP), and TNF alpha and activation of Toll-like receptor-4 (TLR4) [20, 21]. Then massive destruction of the hepatic cells changed into the liver fibrosis [22].

The liver fibrosis stage begins with an increasing load of extracellular matrix (ECM) proteins which indicate the massive damage in hepatocytes, and the persistent rise of liver injury leads to the advanced stage of liver fibrosis. Furthermore, it has been proven that the advanced fibrosis stage consists of 6 times more ECM when compared with the normal. Along with extra deposition of ECM, some associated genes are also expressed such as collagen I, III, and IV, fibronectin, undulin, elastin, laminin, hyaluronan, and proteoglycans [23,24,25,26,27,28] (Table 1).

Table 1 Showing the progressive stage of non-alcoholic fatty liver disease which is started from the initial stage of 5% of the fat deposition in hepatocytes and progressively follows the sequence of the disease like this non-alcoholic fatty liver disease (NAFLD) → steatosis (without inflammation) → non-alcoholic steatohepatitis (NASH) with inflammation → F0 stage without fibrosis → F1 stage portal fibrosis without septa → F2 stage periportal fibrosis → F3 stage bridging fibrosis → liver cirrhosis [29,30,31,32,33]
Full size table

Non-invasive serum biomarkers

Current trend in research of metabolic disorders is trying to reveal the cellular signaling altered in diseased state to find the possible diagnostic biomarkers for non-alcoholic fatty liver disease. Liver biopsy is the gold standard even after long research in metabolic domain to detect the exact stage of fatty liver disease. However, we tried to present all possible serum biomarkers which is specific to each stage of the liver disease as per latest data present on diagnostic biomarkers. There are certain type of the genes and proteins expressed in different pattern such as inflammatory cytokines like (IL-6, TNF-α, NF-kappa β, TLR-4, and IL-1β), fatty acid transporters like proteins (FATP1, FATP2, FATP5), lipid droplet-associated proteins or perilipins (PLIN1, PLIN2, PLIN3, PLIN4, and PLIN5), and extracellular matrix proteins in different stages of the disease. Figure 2 shows the expression of certain serum biomarkers from the early stage of NAFLD to NASH or liver fibrosis in an elaborative pattern.

Fig. 2
figure 2

Showing that the increased expression of certain genes and proteins related to inflammatory, fats, and extracellular matrix (ECM) pathways in early stage of NAFLD to liver-fibrosis stage. The early stage of the disease started from the small amount of fat deposition in liver parenchyma, but progressively, mode of liver disease converted into non-alcoholic steatohepatitis with inflammatory signatures shows increased expression of interlekin-6 (IL-6), interleukin-8 (IL-8), interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), Toll-like receptor-4 (TLR-4), C-reactive protein (CRP), and nuclear factor-kappa beta (NF-kappa β). Activation of fat-related pathways like fatty acid-binding protein-4 (FABP4) and cluster of differentiation 36 (CD36). At the stage of NASH, the lipid droplet-associated proteins perilipin-1 (PLIN1) is highly expressed. Some other NASH-related proteins expression like cytokeratin 18 (CK18), cathepsin D, and ferritin. At this stage, some studies indicate that the disease can be reverse using the combine therapy of vitamin E, pioglitazone, and liraglutide. But after crossing the NASH stage, the liver entered into the emergency zone; the stage is known as liver fibrosis or cirrhosis condition where only liver transplantation is the single option to save the life of the patient. The fibrosis stage begins with increased expression of extracellular matrix proteins like hyaluronic acid, laminin, tissue inhibitor of metalloproteinase (TIMP-1), ferritin, alanine transaminase (ALT), aspartate transaminase (AST), procollagen peptide type III (PIIINP), matrix metalloproteinase (MMP), and procollagen C3 (Pro C3)

Full size image

Multiomics approach on oxidation process in hepatocytes

Recently, the multiomics approaches are targeted digging out the molecular pathway of fatty liver disease, which will be helpful to discover novel biomarkers. The oxidation process is one of the main processes which occur in hepatocyte cells during the disease severity. There are certain fatty acid-derived products that play a keen role in non-alcoholic steatohepatitis conditions. Based on the lipid omics data, it has been proved that the oxidation product of arachidonic acid, 11 hydroxyeicosatetraenoic acid (11-HETE), and linoleic acid oxidation products are significantly increased in NASH patients [34, 35].

Scope of micro-RNAs as biomarkers

Micro-RNAs have special functions to control the posttranscriptional gene silencing and maintain the normal cellular and metabolic homeostasis by regulating the gene expression. After comparing data collected from the serum studies of NAFLD patients and the studies of analysis of the expression of micro-RNA of NAFLD patient with the healthy population, there is a huge difference noticed in both the results. One of recently published data shows the Micro-RNA 29 have the dominant role in non-alcoholic fatty liver disease [36]. However, there are three subtypes of Micro-RNA 29 which are Micro-RNA 29a, Micro-RNA 29b, and Micro-RNA 29c. Among them, Micro-RNA 29a is highly upregulated in NAFLD patients, but Micro-RNA 29b and Micro-RNA 29c do not show any promising effect in clinical specimen of NAFLD patient when compared with the healthy control. Another Micro-RNA such as Micro-RNA 16, Micro-RNA 21, Micro-RNA 122, Micro-RNA 34a, and Micro-RNA 375 show their upregulation in non-alcoholic fatty liver disease patient. An animal study using the apolipoprotein E-deficient mice which is used as a NAFLD model shows the increased expression of Micro-RNA 34a-p and Micro-RNA 375-3p [37]. However, if we look into the later stage of the disease, the expression of Micro-RNA is not the same when we compare with NAFLD patient data. The severity of disease such as early stage of hepatocarcinogenesis shows downregulation of this gene. Apart from the clinical data of NASH patients, it also revealed some new Micro-RNA, which are overexpressed in serum sample like Micro-RNA 21, Micro-RNA 23a, Micro-RNA 26a, Micro-RNA 155, Micro-RNA 200c, Micro-RNA 222, Micro-RNA 224, Micro-RNA 374a, and Micro-RNA 423. These types of research advancement in area of micro-RNA could come up with breakthrough in discovery of new non-invasive serum biomarkers for NAFLD/NASH [38].

Another study shows that micro-RNA that are specific for the fatty liver disease, which is elaborated more below as mentioned in Fig. 3. So, these disease stage-specific miRNAs could be beneficial to discover the non-invasive serum biomarkers for the non-alcoholic fatty liver disease.

Fig. 3
figure 3

Showing that micro-RNA alteration was observed in each stage of the fatty liver disease. Some early-stage-specific micro-RNA like miR-16, miR-1991-5p, miR-193a-5p, and miR-129-5p were highly expressed, and miR-194, miR-135a-3p, and miR-128-p were downregulated [39,40,41,42,43]. Comparatively, in case of NASH, the miR-122-5p, miR-192-5p, miR-4449, miR223, miR-34a, miR-6881-85p, miR-146b, miR-122, and miR-1205 found abundantly expression [44,45,46,47,48,49]. Later stage of the disease like fibrosis/cirrhosis stage also shows some specific upregulation of miRNAs like miR-21, miR-192, and miR-146b [43, 50]

Full size image

Gut microbiome-associated biomarkers

Gut microbiome science related to human physiology is continuously making the remarkable footprints to solve the role of trillions of bacteria present in the gut which play an impactful role in different types of disorders in our body system [51]. Among them, it has been proved that there is a cross talk that happens between the liver and gut with the help of portal vein which connects the entire gut system to the liver [52]. We are aware that the consumption of Western diet or high-fat diet leads to alteration in entire bacterial population in gut microbiota, and this state is well known as dysbiosis [53, 54]. The study of this specific type of bacterial shift could bring the breakthrough to diagnose the non-alcoholic fatty liver disease. There are certain bacterial phyla that are upregulated or downregulated in each stage of the NAFLD. Most of the bacterial phyla follow the same pattern in all stages of the disease, such as Bacteroides which shows their increased expression in early NAFLD and later stage of the disease. Contrastingly, some of the bacterial phyla are very specific to each stage, such as Allisonella which is particularly detected in NASH, and increased expression of Verrucomicrobia is seen in early stage of the NAFLD, but downregulation is seen in the later stage of the disease (liver fibrosis) [55]. Recently, studies show that the bacterial phyla show an abundance in hepatocyte fibrosis, such as Tenericutes and Actinobacteria, and a decrease in the abundance of Bacteroidetes [56] (Fig. 4).

Fig. 4
figure 4

Showing that the dysbiosis condition after the patient diagnosed with non-alcoholic fatty liver disease, which results imbalance in gut bacterial population. Initial phase of NAFLD shows upregulation of certain bacterial phyla which are Parabacteroides, Porphyromonas, Bacteroides, Prevotella, Fusobacteria, Lentisphaerae, Robinsoniella, Dorea, Verrucomicrobia, Escherichia, Megasphaera, Bifidobacterium, Shigella, and Eggerthella and decreasing population of Coprobacter, Ruminococcus, Coprococcus, Anaerosporobacter, Faecalibacterium, Moryella, Pseudobutyrivibrio, Eubacterium, Odoribacter, Oscillospira, Subdoligranulum, Holdemania, and Anaerotruncus. When we focus on the NASH stage, several new bacterium phyla detected on progressive stage of the disease and show the increased population of Bacteroides, Allisonella, Proteobacteria, TM7, Klebsiella, and Parabacteroides. Oppositely, there are certain bacterial phyla population which was decreasing which includes Oscillospira, Roseburia, Eubacterium, and Faecalibacterium. Liver fibrosis stage shows decrease bacterial phyla of Bacteroidetes and Verrucomicrobia, whereas the increased population of Bacteroides, Actinobacteria, and Tenericutes reported in end stage of the fatty liver (liver fibrosis)

Full size image

Interestingly, some bacterial phyla are specifically detected abundantly in early stage of NAFLD, whereas those bacterial phyla not observed significantly change in later stage of the diseases such as Fusobacteria, Verrucomicrobia, and Lentisphaerae which could lead to discovery of the scope of diagnostic markers for the NAFLD [57].

Lipid droplets perilipin family protein

Lipid droplet-associated protein like perilipin 1–5 (PLIN1, PLIN2, PLIN3, PLIN4, and PLIN5) and another linked pathways involved in synthesis and fate of lipid droplets could be another approach to discover the biomarkers for the non-alcoholic fatty liver disease [58, 59]. Most of the in vivo study already proved that the expression of PLIN1 is highly upregulated in NAFLD. The macrovesicular steatosis is specific to PLIN1 expression, and PLIN1 stabilized the large lipid droplets and dominantly present in white adipose tissue [60, 61]. PLIN2 is abundantly found in the liver organ, and most of the studies previously claimed its direct involvement in fatty liver disease progression due to their important role in lipid accumulation in hepatocytes. These studies somewhere show their participation in inflammatory pathways activation, but the whole mechanism is not clearly defined until now [62,63,64]. Furthermore, PLIN2 knockout studies show improvement in NASH condition. PLIN3 sometime called as mannose-6-phosphate-binding proteins shows their importance in lipid droplets biogenesis [65]. However, inhibition of PLIN3 presents their role in reduction of inflammation proportionally reducing the action of prostaglandin synthase and improves the hepatosteatosis condition by suppressing the inflammation [66]. Upregulation of PLIN4 reveals the micro-steatosis state in hepatocytes, and PLIN4 expression in nascent lipid droplets indicated that it is integrated into nascent lipid droplets together with freshly generated triacylglycerols, so it may be possible the inhibition of PLIN4 shows their preventive action in NAFLD and also could be helpful to design the further study as an biomarkers for micro-steatosis condition [59]. Unlike other perilipins, the PLIN5 expression is observed at the stage of hepatocellular carcinoma (HCC) and also execute the function to regulate the lipid homeostasis by inhibiting the lipolysis [67]. Surprisingly, murine model of HCC also presents the evidence to play a keen role in tumor progression, but most of the cellular signaling is still unclear [68]. In future, this could be another best consideration to find the novel biomarkers for the later stage of liver diseases such as advance fibrosis or HCC. In conclusion, although the lipid droplets perilipin family proteins (PLIN 1–5) are understudied proteins, understanding their mechanisms may pave the way for the development of effective treatments and biomarkers for NAFLD/NASH.

Lipoproteins

The liver is the major organ for the metabolic process which is also involved in fat metabolism, and it highly participates in the transport of hydrophobic lipoprotein with the help of apolipoproteins involvement in their transport mechanism. Lipoproteins are broadly categorized into three classes in the human body: chylomicron, very low-density lipoprotein, and high-density lipoprotein. NAFLD and dyslipidemia, a collection of abnormalities in plasma lipoproteins including triglyceride-rich very low-density lipoproteins, are interlinked with each other, but their mechanism of action is still unknown. Apolipoproteins are a group of predominantly liver-derived proteins found in serum lipoproteins; they not only play an essential intracellular role in hepatic lipoprotein but also play an essential extracellular role in lipid transfer between key organs through circulation. Various clinical studies prove that hepatic lipoproteins are the major player to regulate the fat deposition in hepatocytes.

Apolipoprotein E

Adipose tissue that stores too much energy contributes to the development and spread of obesity, which has a number of harmful side effects including metabolic syndrome and cardiovascular illnesses. There are several lipoproteins and their components that are directly or indirectly linked with the lipolysis process in adipocytes, but some of them play a very keen role to regulate the fat metabolic process such as apolipoprotein E. Apolipoprotein E is the core component of lipoproteins which is dominantly expressed in adipose tissues and sometimes called arginine-rich apolipoprotein due to high content of arginine amino acids. Previously recorded data proved that apolipoprotein E contributes to lipoprotein internalization and degradation via the process of endocytosis which compels that there could be a better role of apolipoprotein in metabolic disorders, especially in fat accumulation in hepatocytes [69]. Recently, in data gathered from the animal study, the apo E-deficient mouse with methionine choline-deficient (MCD) diet or Western diet (WD) shows severe steatosis and high content of VLDL in a hepatic system with the increased expression profile of proinflammatory cytokines such as IL-1β, TNF-α, and MCP1 [70].

Role of dihydroceramide

Recently, a study claims that the dihydroceramide in triglycerides-enriched VLDL shows involvement in the signature of non-alcoholic fatty liver disease which was earlier considered for the type 2 diabetes-associated markers, and these TGs-enriched VLDL particles participate in the progression of atherogenic dyslipidemia [71, 72]. Contrarily, increased expression of dihydroceramide in diabetic patients also hampers the normal homeostasis of metabolic pathways of fat which results in the excessive amount of fat deposition in the hepatic system and ultimately leads to non-alcoholic fatty liver disease. The whole mechanism of dihydroceramide is still unclear, but the all-associated genes and proteins of dihydroceramide could be a better approach to finding the novel biomarker of non-alcoholic fatty liver disease associated with type 2 diabetes.

Gene expression studies

The genes involved in tissue remodeling processes and play their role in cell–matrix interaction show highly expression in NASH (F1–F4). Contrastingly, the genes involved in encoding of lipid protein metabolism seem to be downregulated. The differentiation between the early stage of NAFLD and NASH is the major question to find the novel biomarkers of the progressive stage of the liver disease. Conclusively, in early stage of NAFLD, most of the inflammatory pathways are activated and genes expressed abundantly, comparing with the NASH or the later stage of the disease the certain new genes and proteins activated which are shown in Table 2 below.

Table 2 Showing some less studied biomarkers to differentiate between the early stage of NAFLD and NASH [73, 74]
Full size table

Conclusion

Non-alcoholic fatty liver disease is a highly complicated mechanism that is linked to a wide range of metabolic disorders. As a disease progresses, it develops a variety of signs and cellular changes that disrupt the network of genes and proteins results to make complicated diagnostic criteria of each stage of the non-alcoholic fatty liver disease. We are unable to conclude the gold standard non-invasive diagnostic methods for the non-alcoholic fatty liver disease to their most severity form of liver cirrhosis till date. This review will open a window of new speculative notions in the field of non-alcoholic fatty liver disease to find the novel biomarkers by concentrating on the numerous genes and proteins that have previously demonstrated their potential involvement in disease state. Newly studies on gut microbiome show a lot of bacterial population and are altered in different stages, some of the bacterial population expression level is same in all stages of NAFLD, but some could be more specific, for example, the study on 16 NASH patient shows higher abundancy of Allisonella present in fecal [55]. These types of research need further study evidence on higher population for data reproducibility and accuracy which can be impactful to design a diagnostic kit using the stool sample. Another leading research studies on micro-RNAs in field of metabolic diseases, such as fatty liver disease, have shown highly encouraging results that can be used to find serum biomarkers for NAFLD/NASH. Apart from this, some of the miRNAs are detected at the later stage of the disease specially fibrosis, like miR-21, miR-192, and miR-146b. These could be good biomarkers to detect the fibrosis stage. Furthermore, that increased population of Tenericutes and Actinobacteria could be best findings for the diagnosis of liver fibrosis. Previously recorded data defined the role of dihydroceramides in type 2 diabetes mellitus; however, it participates in metabolic pathways through high content of TGs in VLDL particles and helps in disease progression, and it may be possible there could be a strong chance that patient with type 2 diabetes mellitus may develop fatty liver disease at later stage. Some less focused serum gene expression alteration in NAFLD including serpin family, lipid droplet-associated proteins (PLIN1-5), and paraoxygenase family proteins also need further study to prove the exact regulatory pathway hampered by those genes and the way in which better diagnostic biomarkers methods could be adopted that could replace the invasive techniques in diagnostic area.

Availability of data and materials

Not applicable.

References

  1. Zarghamravanbakhsh P, Frenkel M, Poretsky LJMO (2021) Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol Open 12:100149

    PubMed  PubMed Central  CAS  Google Scholar 

  2. Tan EXX, Lee JWJ, Jumat NH, Chan WK, Treeprasertsuk S, Goh GBB, Fan JG et al (2022) Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism. 126:154911

    PubMed  CAS  Google Scholar 

  3. Zhang X, Heredia NI, Balakrishnan M, Thrift AP (2021) Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: results from NHANES 2017–2018. Plos One. 16:e0252164

    PubMed  PubMed Central  CAS  Google Scholar 

  4. Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZMJH (2022) Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology 75:1204–1217

    PubMed  CAS  Google Scholar 

  5. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q et al (2022) 2019 global NAFLD prevalence-a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 20(12):2809-2817.e28

    PubMed  Google Scholar 

  6. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. 2022

  7. Xian Y-X, Weng J-P, Xu F (2021) MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 134:8–19

    CAS  Google Scholar 

  8. Vilar-Gomez E, Nephew LD, Vuppalanchi R, Gawrieh S, Mladenovic A, Pike F, Samala N et al (2022) High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. Hepatology. 75:1491–1506

    PubMed  Google Scholar 

  9. Lazarus JV, Palayew A, Carrieri P, Ekstedt M, Marchesini G, Novak K, Ratziu V et al (2021) European ‘NAFLD Preparedness Index’—is Europe ready to meet the challenge of fatty liver disease? JHEP Rep. 3:100234

    PubMed  PubMed Central  Google Scholar 

  10. Poonawala A, Nair SP, Thuluvath PJJH (2000) Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32:689–692

    PubMed  CAS  Google Scholar 

  11. Maurice J, Manousou PJCm (2018) Non-alcoholic fatty liver disease. Clin Med (Lond) 18:245

    PubMed  Google Scholar 

  12. Akshintala D, Chugh R, Amer F, Cusi KJE. Nonalcoholic fatty liver disease: the overlooked complication of type 2 diabetes. 2019

  13. Lee C-H, Han K-D, Kim DH, Kwak M-SJFie (2021) The repeatedly elevated fatty liver index is associated with increased mortality: a population-based cohort study. Front Endocrinol (Lausanne) 12:638615

    PubMed  Google Scholar 

  14. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A et al (2016) The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64:1577–1586

    PubMed  Google Scholar 

  15. Vernon G, Baranova A, Younossi Z M (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285

    PubMed  CAS  Google Scholar 

  16. Fitzpatrick E, Dhawan A (2014) Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 20:10851

    PubMed  PubMed Central  Google Scholar 

  17. Heyens LJ, Busschots D, Koek GH, Robaeys G, Francque SJFim (2021) Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front med 8:615978

    Google Scholar 

  18. Benedict M, Zhang XJWjoh (2017) Non-alcoholic fatty liver disease: an expanded review. World J Hepatol 9:715

    PubMed  PubMed Central  Google Scholar 

  19. Dhamija E, Paul SB, Kedia SJTIjomr (2019) Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: an increasing concern. Indian J Med Res 149:9

    PubMed  PubMed Central  CAS  Google Scholar 

  20. Zisser A, Ipsen DH, Tveden-Nyborg P (2021) Hepatic stellate cell activation and inactivation in NASH-fibrosis—roles as putative treatment targets? Biomedicines. 9:365

    PubMed  PubMed Central  CAS  Google Scholar 

  21. Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, Luo M (2022) Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front Immunol. 13:880298

    PubMed  PubMed Central  CAS  Google Scholar 

  22. Neuschwander-Tetri BA (2017) Non-alcoholic fatty liver disease. BMC Med. 15(1):145

    Google Scholar 

  23. Ala-Kokko L, Pihlajaniemi T, Myers JC, Kivirikko K, Savolainen EJBJ (1987) Gene expression of type I III and IV collagens in hepatic fibrosis induced by dimethylnitrosamine in the rat. Biochem J 244:75–79

    PubMed  PubMed Central  CAS  Google Scholar 

  24. Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DG, Loomba R, Surabattula R et al (2020) Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int 40:736–750

    PubMed  CAS  Google Scholar 

  25. Altrock E, Sens C, Wuerfel C, Vasel M, Kawelke N, Dooley S, Sottile J et al (2015) Inhibition of fibronectin deposition improves experimental liver fibrosis. J Hepatol 62:625–633

    PubMed  CAS  Google Scholar 

  26. Kanta J (2016) Elastin in the liver. Front Physiol 7:491

    PubMed  PubMed Central  Google Scholar 

  27. Albeiroti S, Soroosh A, de la Motte CA (2015) Hyaluronan’s role in fibrosis: a pathogenic factor or a passive player? Biomed Res Int. 2015

    PubMed  PubMed Central  Google Scholar 

  28. Roeb EJMB (2018) Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol 68:463–473

    PubMed  Google Scholar 

  29. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218

    PubMed  PubMed Central  CAS  Google Scholar 

  30. Chen Y-Y, Yeh MM (2021) Non-alcoholic fatty liver disease: a review with clinical and pathological correlation. J Formos Med Assoc 120:68–77

    PubMed  CAS  Google Scholar 

  31. Axley P, Mudumbi S, Sarker S, Kuo Y-F, Singal A (2018) Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications. Plos One. 13:e0197117

    PubMed  PubMed Central  Google Scholar 

  32. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321

    PubMed  Google Scholar 

  33. Kleiner DE, Makhlouf HR (2016) Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis 20:293–312

    PubMed  Google Scholar 

  34. Santoro N, Caprio S, Giannini C, Kim G, Kursawe R, Pierpont B, Shaw MM et al (2014) Oxidized fatty acids: a potential pathogenic link between fatty liver and type 2 diabetes in obese adolescents? Mary Ann Liebert Inc, New Rochelle

    Google Scholar 

  35. Di Mauro S, Scamporrino A, Filippello A, Di Pino A, Scicali R, Malaguarnera R, Purrello F et al (2021) Clinical and molecular biomarkers for diagnosis and staging of NAFLD. Int J Mol Sci 22:11905

    PubMed  PubMed Central  Google Scholar 

  36. Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn SJM. Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). 2018;7:215–222

  37. López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, et al. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. 2021;14:dmm049173

  38. Vulf M, Shunkina DA, Komar A, Bograya M, Zatolokin P, Kirienkova E, Gazatova N, et al. Analysis of miRNAs profiles in serum of patients with steatosis and steatohepatitis. 2021:2398

  39. Lai C-Y, Yeh K-Y, Lin C-Y, Hsieh Y-W, Lai H-H, Chen J-R, Hsu C-C, et al. MicroRNA-21 plays multiple oncometabolic roles in the process of NAFLD-related hepatocellular carcinoma via PI3K/AKT, TGF-β, and STAT3 signaling. 2021;13:940

  40. Zhang T, Yang Z, Kusumanchi P, Han S, Liangpunsakul SJFim. Critical role of microRNA-21 in the pathogenesis of liver diseases. 2020;7:7

  41. Newman LA, Useckaite Z, Johnson J, Sorich MJ, Hopkins AM, Rowland AJB (2022) Selective isolation of liver-derived extracellular vesicles redefines performance of miRNA biomarkers for non-alcoholic fatty liver disease. Biomedicines 10:195

    PubMed  PubMed Central  CAS  Google Scholar 

  42. Li Y, Luan Y, Li J, Song H, Li Y, Qi H, Sun B, et al. Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism. 2020;14:1057–1074

  43. Aghajanzadeh T, Talkhabi M, Zali MR, Hatami B, Baghaei K. Diagnostic and pathogenesis performance of circulating miR-146b, miR-194, and miR-214 in liver fibrosis. 2022

  44. Kim TH, Lee Y, Lee Y-S, Gim J-A, Ko E, Yim SY, Jung YK et al (2021) Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Sci Rep 11:1–9

    Google Scholar 

  45. He Y, Rodrigues RM, Wang X, Seo W, Ma J, Hwang S, Fu Y, et al. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223–enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. 2021;131

  46. Xu Y, Zhu Y, Hu S, Pan X, Bawa FC, Wang HH, Wang DQ-H, et al. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease. 2021;51:101244

  47. Albadawy R, Agwa SH, Khairy E, Saad M, El Touchy N, Othman M, Matboli MJB. Clinical significance of HSPD1/MMP14/ITGB1/miR-6881–5P/Lnc-SPARCL1–1: 2 RNA panel in NAFLD/NASH diagnosis: Egyptian pilot study. 2021;9:1248

  48. Musa NI, Agwa SH, Faheem HA, El-din AMGAJQAIJoM. Evaluation of microRNA-122 as a non-invasive diagnostic biomarker for non-alcoholic fatty liver disease and NASH related cirrhosis. 2021;114:hcab100. 010

  49. Gadallah SH, Eissa S, Ghanem HM, Ahmed EK, Hasanin AH, El Mahdy MM, Matboli MJB, et al. Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. 2021;140:111781

  50. Ren F-j, Yao Y, Cai X-y, Fang G-yJFiP. Emerging role of MiR-192–5p in human diseases. 2021;12:614068

  51. Guinane CM, Cotter PD (2013) Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol 6:295–308

    PubMed  PubMed Central  Google Scholar 

  52. Brandl K, Kumar V, Eckmann L (2017) Gut-liver axis at the frontier of host-microbial interactions. Am J Physiol Gastrointest Liver Physiol 312:G413–G419

    PubMed  PubMed Central  Google Scholar 

  53. Bortolin R, Vargas A, Gasparotto J, Chaves P, Schnorr CE, Martinello KB, Silveira A et al (2018) A new animal diet based on human Western diet is a robust diet-induced obesity model: comparison to high-fat and cafeteria diets in term of metabolic and gut microbiota disruption. Int J Obes (Lond) 42:525–534

    PubMed  CAS  Google Scholar 

  54. Martinez KB, Leone V, Chang EBJGm. Western diets, gut dysbiosis, and metabolic diseases: are they linked? 2017;8:130–142

  55. Wong VW-S, Tse C-H, Lam TT-Y, Wong GL-H, Chim AM-L, Chu WC-W, Yeung DK-W, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis–a longitudinal study. 2013;8:e62885

  56. Li Z, Ni M, Yu H, Wang L, Zhou X, Chen T, Liu G, et al. Gut microbiota and liver fibrosis: one potential biomarker for predicting liver fibrosis. 2020;2020

  57. Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, Bross C et al (2019) Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology 157:1109–1122

    PubMed  CAS  Google Scholar 

  58. Sharma AJFJoPS. Lipid droplets associated perilipins protein insights into finding a therapeutic target approach to cure non-alcoholic fatty liver disease (NAFLD). 2022;8:1–11

  59. Minehira K, Gual PJVBRN-AFLD. Role of lipid droplet proteins in the development of NAFLD and hepatic insulin resistance. 2018:55–77

  60. Itabe H, Yamaguchi T, Nimura S, Sasabe NJLih, disease. Perilipins: a diversity of intracellular lipid droplet proteins. 2017;16:1–11

  61. Carr RM, Dhir R, Mahadev K, Comerford M, Chalasani NP, Ahima RS (2017) Perilipin staining distinguishes between steatosis and nonalcoholic steatohepatitis in adults and children. Clin Gastroenterol Hepatol 15:145–147

    PubMed  Google Scholar 

  62. Najt CP, Senthivinayagam S, Aljazi MB, Fader KA, Olenic SD, Brock JR, Lydic TA, et al. Liver-specific loss of perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis. 2016;310:G726-G738

  63. Irungbam K, Churin Y, Matono T, Weglage J, Ocker M, Glebe D, Hardt M, et al. Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2. 2020;100:454–465

  64. Imai Y, Boyle S, Varela GM, Caron E, Yin X, Dhir R, Dhir R, et al. Effects of perilipin 2 antisense oligonucleotide treatment on hepatic lipid metabolism and gene expression. 2012;44:1125–1131

  65. Kimmel AR, Brasaemle DL, McAndrews-Hill M, Sztalryd C, Londos C (2010) Adoption of perilipin as a unifying nomenclature for the mammalian PAT-family of intracellular lipid storage droplet proteins. J Lipid Res 51:468–471

    PubMed  PubMed Central  CAS  Google Scholar 

  66. Nose F, Yamaguchi T, Kato R, Aiuchi T, Obama T, Hara S, Yamamoto M, et al. Crucial role of perilipin-3 (TIP47) in formation of lipid droplets and PGE2 production in HL-60-derived neutrophils. 2013;8:e71542

  67. Mass Sanchez PB, Krizanac M, Weiskirchen R, Asimakopoulos AJIJoMS. Understanding the role of perilipin 5 in non-alcoholic fatty liver disease and its role in hepatocellular carcinoma: a review of novel insights. 2021;22:5284

  68. Asimakopoulou A, Vucur M, Luedde T, Schneiders S, Kalampoka S, Weiss TS, Weiskirchen RJC. Perilipin 5 and lipocalin 2 expression in hepatocellular carcinoma. 2019;11:385

  69. Li Y-h, Liu L (2014) Apolipoprotein E synthesized by adipocyte and apolipoprotein E carried on lipoproteins modulate adipocyte triglyceride content. Lipids Health Dis 13:1–7

    CAS  Google Scholar 

  70. Schierwagen R, Maybüchen L, Zimmer S, Hittatiya K, Bäck C, Klein S, Uschner FE et al (2015) Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep 5:1–14

    Google Scholar 

  71. Carlier A, Phan F, Szpigel A, Hajduch E, Salem J-E, Gautheron J, Le Goff W, et al. Dihydroceramides in triglyceride-enriched VLDL are associated with nonalcoholic fatty liver disease severity in type 2 diabetes. 2020;1:100154

  72. Wittenbecher C, Cuadrat R, Johnston L, Eichelmann F, Jäger S, Kuxhaus O, Prada M et al (2022) Dihydroceramide-and ceramide-profiling provides insights into human cardiometabolic disease etiology. Nat Commun 13:1–13

    Google Scholar 

  73. Neuman MG, Cohen LB, Nanau RM (2014) Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol 28:607–618

    PubMed  PubMed Central  Google Scholar 

  74. Subudhi S, Drescher HK, Dichtel LE, Bartsch LM, Chung RT, Hutter MM, Gee DW et al (2022) Distinct hepatic gene-expression patterns of NAFLD in patients with obesity. Hepatol Commun 6:77–89

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Author statement

We the undersigned declare that this manuscript is original, has not been published before, and is not currently being considered for publication elsewhere. We confirm that the manuscript has been read and approved by all named authors, and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We understand that the corresponding author is the sole contact for the editorial process. He/she is responsible for communicating with the other authors about progress, submissions of revisions, and final approval of proofs.

Aman Sharma

Corresponding author and on behalf of other authors.

Funding

There is no funding provided to design the study, interpretation, and collection of data.

Author information

Author notes

  1. Pooja Dudeja, Taishee Pal and Aman Sharma contributed equally to this work.

Authors and Affiliations

  1. Department of Biology, Faculty of Medicine, Masaryk University, Brno, 61700, Czech Republic, India

    Pooja Dudeja

  2. Department of Applied Microbiology, School of Biosciences and Technology, VIT University, Kalyani, West Bengal, 741235, India

    Taishee Pal

  3. Department of Pharmacology & Toxicology, NIPER, Kolkata, West Bengal, 700054, India

    Aman Sharma

Authors
  1. Pooja Dudeja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taishee Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aman Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by AS, PD, and TP. The first draft of the manuscript was written by AS, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Aman Sharma.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dudeja, P., Pal, T. & Sharma, A. The novel approach for non-invasive diagnostic biomarkers from an early stage of NAFLD to advanced fibrosis. Egypt Liver Journal 13, 51 (2023). https://doi.org/10.1186/s43066-023-00287-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43066-023-00287-3

Keywords